Showing results (611-620 of 5,680) with videos related to

Sort By:
Pageof 568
The Oncologist|February 22, 2001
Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancerE E Vokes
The Oncologist|December 6, 2019
Prognostic Values of Long Noncoding RNA linc00152 in Various Carcinomas: An Updated Systematic Review and Meta-AnalysisHan Wang, Yang Liu, Aifa Tang
The Oncologist|December 28, 2019
Weekly Chemotherapy of 5-Fluorouracil plus Cisplatin Concurrent with Radiotherapy for Esophageal Squamous Cell Carcinoma Patients with Postoperative Locoregional Recurrence: Results from a Phase II StudyBaoqing Chen, Qiwen Li, Qiaoqiao Li, et al.
The Oncologist|December 19, 2019
Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal CancerMohamed E Salem, Francesca Battaglin, Richard M Goldberg, et al.
The Oncologist|December 19, 2019
Incorporating Patient-Reported Outcome Measures into Breast Surgical Oncology: Advancing Toward Value-Based CareMirelle Lagendijk, Elizabeth Mittendorf, Tari A King, et al.
The Oncologist|February 25, 2020
Designing an Effective Colorectal Cancer Screening Program in Egypt: A Qualitative Study of Perceptions of Egyptian Primary Care Physicians and SpecialistsLori Brand Bateman, Somaia Khamess, Salah-Eldin Abdelmoneim, et al.
The Oncologist|March 13, 2020
Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint InhibitorsDylan J Martini, Yuan Liu, Julie M Shabto, et al.
The Oncologist|March 13, 2020
Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?Alice Avancini, Giulia Sartori, Anastasios Gkountakos, et al.
The Oncologist|March 13, 2020
Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) ChemotherapyLee Schwartzberg, Rudolph Navari, Rebecca Clark-Snow, et al.
The Oncologist|March 13, 2020
Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility AnalysisJohn J Kim, Thomas McFarlane, Stephen Tully, et al.
Pageof 568